<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48687">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027428</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-007-NSCL-003</org_study_id>
    <nct_id>NCT02027428</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer</brief_title>
  <acronym>aboundsqm</acronym>
  <official_title>A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel (Abraxane®) Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance treatment of advanced stage squamous cell NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III, randomized, open-label, cross-over, multicenter study of nab-paclitaxel plus
      best palliative care or best palliative care alone as maintenance treatment after response
      or stable disease with nab-paclitaxel plus carboplatin as induction in subjects with
      squamous cell NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants to survive without progressing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Approximately 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants who survive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Approximately 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients who achieve an overall response according to Response Evaluation Criteria in Solid Tumors RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Squamous Cell Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Abraxane + Best Supportive Care (BSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will occur in two phases - induction and maintenance.  During induction, the subject will receive Abraxane plus carboplatin as standard of care.  At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase.  Maintenance dosing on this arm includes Abraxane plus best supportive care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care (BSC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane  (Induction)</intervention_name>
    <description>100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care</description>
    <arm_group_label>Abraxane + Best Supportive Care (BSC)</arm_group_label>
    <other_name>nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (Induction)</intervention_name>
    <description>6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion</description>
    <arm_group_label>Abraxane + Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane (Maintenance)</intervention_name>
    <description>100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care</description>
    <arm_group_label>Abraxane + Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care (Maintenance)</intervention_name>
    <description>The best palliative care per investigator (including but not limited to:  antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents</description>
    <arm_group_label>Abraxane + Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane  (Induction)</intervention_name>
    <description>100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care</description>
    <arm_group_label>Best Supportive Care (BSC)</arm_group_label>
    <other_name>nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (Induction)</intervention_name>
    <description>6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care</description>
    <arm_group_label>Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care (Maintenance)</intervention_name>
    <description>The best palliative care per investigator (including but not limited to:  antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents</description>
    <arm_group_label>Best Supportive Care (BSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 18 years of age at the time of signing the Informed Consent Form. 2.
             Understand and voluntarily provide written consent to the Informed Consent Form prior
             to conducting any study related assessments/procedures.

             3. Able to adhere to the study visit schedule and other protocol requirements Disease
             Specific 4. Histologically or cytologically confirmed Stage IIIB or IV squamous cell
             Non Small Cell Lung Cancer at study entry.

             5. No prior history of other malignancies, except basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.

             6. Radiographically documented measurable disease at study entry (as defined in
             Appendix A; lesions in previously irradiated areas [or areas with local therapy]
             should not be selected as target lesions, unless there has been demonstrated
             progression in the lesion).

             7. No prior chemotherapy for the treatment of metastatic disease at study entry.
             Adjuvant chemotherapy is permitted providing cytotoxic chemotherapy was completed 12
             months prior to starting the study and without disease recurrence.

             8. Absolute neutrophil count ≥ 1500 cells/mm3. 9. Platelets ≥ 100,000 cells/mm3. 10.
             Hemoglobin ≥ 9 g/dL. 11. Aspartate transaminase/serum glutamic oxaloacetic
             transaminase, alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper
             limit of normal range or ≤ 5.0 × upper limit of normal range if liver metastases.

             12. Total bilirubin ≤ 1.5 × upper limit of normal range except in cases of Gilbert's
             disease and liver metastases.

             13. Creatinine ≤ 1.5 mg/dL. 14. Expected survival of &gt; 12 weeks for the Induction
             part of the study. 15. Eastern Cooperative Oncology Group performance status 0 or 1.
             16. For Maintenance part of the study, subjects must have received at least one dose
             of nab-paclitaxel in each of the 4 cycles during Induction Pregnancy 17. Females of
             childbearing potential [defined as a sexually mature woman who (1) have not undergone
             hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the
             surgical removal of both ovaries) or (2) have not been naturally postmenopausal for
             at least 24 consecutive months (ie, has had menses at any time during the preceding
             24 consecutive months)] must:

               1. Have a negative pregnancy test as verified by the study doctor prior to starting
                  study therapy. She must agree to ongoing pregnancy testing during the course of
                  the study, and after end of study therapy. This applies even if the subject
                  practices true abstinence* from heterosexual contact.

               2. Either commit to true abstinence* from heterosexual contact (which must be
                  reviewed on a monthly basis) or agree to use, and be able to comply with,
                  effective contraception without interruption, 28 days prior to starting study
                  drug, during the study therapy (including dose interruptions), and for 3 months
                  after discontinuation of study therapy.

                  Male subjects must:

               3. practice true abstinence* or agree to use a condom during sexual contact with a
                  pregnant female or a female of childbearing potential while participating in the
                  study, during dose interruptions and for at least 3 months following study drug
                  discontinuation, even if he has undergone a successful vasectomy.

                  * True abstinence is acceptable when this is in line with the preferred and
                  usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation,
                  symptothermal, post-ovulation methods) and withdrawal are not acceptable methods
                  of contraception].

                  18. Females must abstain from breastfeeding during study participation and 3
                  months after IP discontinuation.

                  Exclusion Criteria:

          -  The presence of any of the following will exclude a subject from enrollment into the
             Induction, Maintenance, or Cross-over parts of the study (except if specified at
             study entry only):

               1. Evidence of active brain metastases, including leptomeningeal involvement (prior
                  evidence of brain metastasis are permitted only if treated and stable and off
                  therapy for ≥ 42 days prior to signing Informed Consent Form).

               2. Only evidence of disease is non measurable at study entry.

               3. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology
                  Criteria for Adverse Events v4.0).

               4. Venous thromboembolism within 6 months prior to signing Informed Consent Form.

               5. Current congestive heart failure (New York Heart Association class II-IV).

               6. Myocardial infarction within 6 months prior to signing Informed Consent Form.

               7. Treatment with any investigational product within 28 days prior to signing
                  Informed Consent Form.

               8. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin.

               9. Currently enrolled in any other clinical protocol or investigational trial that
                  involved administration of experimental therapy and/or therapeutic devices.

              10. Any other clinically significant medical condition and/or organ dysfunction that
                  will interfere with the administration of the therapy according to this
                  protocol.

              11. Any condition including the presence of laboratory abnormalities, which places
                  the subject at unacceptable risk if he/she were to participate in the study.

              12. Any condition that confounds the ability to interpret data from the study.

              13. Pregnant and nursing females.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teng Jin Ong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duong Ngyuen, Pharm. D.</last_name>
    <phone>(415) 839-7097</phone>
    <email>dnguyen@celgene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenny Sheikh, BA</last_name>
    <phone>732-652-6318</phone>
    <email>jsheikh@celgene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Albumin bound paclitaxel</keyword>
  <keyword>Taxanes</keyword>
  <keyword>Maintenance trials</keyword>
  <keyword>Celgene</keyword>
  <keyword>Abraxane</keyword>
  <keyword>ABI-007</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Cancer of the Lung</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Abound.sqm</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
